Products V260 + Placebo to V260 + OPV + DTaP
V260 + Placebo to V260 + OPV + DTaP Phase 3 Completed 📈 Rising Rotavirus Gastroenteritis
Rotavirus Gastroenteritis
May 30, 2014 → Jun 11, 2015
About V260 + Placebo to V260 + OPV + DTaP V260 + Placebo to V260 + OPV + DTaP is a phase 3 stage product being developed by Merck for Rotavirus Gastroenteritis. The current trial status is completed. This product is registered under clinical trial identifier NCT02062385. Target conditions include Rotavirus Gastroenteritis.
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT02062385 Phase 3 Completed May 30, 2014 Jun 11, 2015 Rotavirus Gastroenteritis
Product Company Stage Hype Score Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Rotarix™ administered concomitantly with Tritanrix™ HepB (DTwP) + Comparator: RotaTeq™ administered concomitantly with INFANRIX™ (DTaP) Merck Phase 3 RotaTeq™, rotavirus vaccine, live, oral, pentavalent + Comparator: Placebo matching RotaTeq™ Merck Phase 3 Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Oral Poliovirus Vaccine (OPV) + Comparator: Oral Poliovirus Vaccine (OPV) (staggered) Merck Phase 3 RotaTeq (V260) + IPV Merck Phase 3 Rotateq™ + Comparator: Placebo Merck Phase 3 RotaTeq™ (V260) + DTP-IPV Merck Approved Comparator: RotaTeq + Comparator: Placebo + Comparator: RotaTeq + Placebo Merck Phase 1 Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Placebo Merck Phase 3 rotavirus vaccine, live, oral, pentavalent + Placebo Merck Phase 3 Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Placebo + Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: Placebo Merck Phase 1 Rotavirus Vaccine, Live, Oral, Pentavalent + Comparator: placebo + Comparator: Infanrix(tm) Hexa Merck Phase 3 RotaTeq™ experimental formulation + RotaTeq™ existing formulation Merck Phase 3 Rotarix + RotaTeq Merck Phase 3 Rotavirus Vaccine, Live, Oral, Pentavalent (V260, RotaTeq™) + Comparator: Comparator: Placebo (unspecified) Merck Phase 3
Other Products from Merck